Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire
2000/04/01 by Douglas A. Drossman, Donald L. Patrick, William E. Whitehead +5 · 29 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Gastrointestinal motility and disorders #Inflammatory Bowel Disease #Microscopic Colitis
paper · doi:10.1111/j.1572-0241.2000.01941.x
Abstract
OBJECTIVE: There has been growing interest in the investigation of health-related quality of life (HRQOL) among patients with gastrointestinal (GI) disorders. We recently reported on the development and preliminary validation of the IBS-QOL, a specific quality-of-life measure for irritable bowel syndrome (IBS). The aim of this study was to determine the longitudinal construct validity (responsiveness) of the IBS-QOL. METHODS: Female patients enrolled in a multicenter treatment trial for functional bowel disorders were studied pre- and posttreatment with the IBS-QOL and other health status measures. Based on the response to treatment for several variables (pain/14-day score, daily function, and days in bed/3 months), patients were stratified into Responders, Partial Responders, and Nonresponders. Change scores in the IBS-QOL were then statistically compared with changes in the other variables to determine their correlation and whether Responders were significantly different from non- and Partial Responders on the IBS-QOL. RESULTS: There was a significant correlation between change scores on the IBS-QOL and the other measures of treatment effect (Pain/14 days, r = 0.25, p < 0.002; Sickness Impact Profile [SIP] Total Score, r = 0.28, p < 0.0004). In addition, the IBS-QOL scores significantly differentiated Responders from Nonresponders for most of the variables tested (regression trend test for Pain/14 days, p < 0.04; SIP Total, p < 0.0001; SIP Physical, p < 0.0001; SIP Psychosocial, p < 0.002, and SIP Eating, p < 0.04). CONCLUSION: The IBS-QOL is responsive to treatment in a referral-based clinical population of patients with functional bowel disorders.
Cited by
- In-person therapist-delivered hypnotherapy versus smartphone-based self-guided hypnotherapy in IBS: a multicentre three-armed randomised controlled trial
- Effects of empathic and positive communication in healthcare consultations: a systematic review and meta-analysis
- Pain Catastrophizing and Clinical Outcomes Among Patients Receiving a Novel Cognitive-Behavioral Therapy for Irritable Bowel Syndrome: An Experimental Therapeutics Approach
- The low FODMAP diet in the management of irritable bowel syndrome: an evidence‐based review of FODMAP restriction, reintroduction and personalisation in clinical practice
- Cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety. [europepmc]
- Predictors of patient-assessed illness severity in irritable bowel syndrome. [europepmc]
- Evaluation of the Birmingham IBS symptom questionnaire. [europepmc]
- Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. [europepmc]
- A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. [europepmc]
- A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome. [europepmc]
- International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. [europepmc]
- A treatment trial of acupuncture in IBS patients. [europepmc]
- Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. [europepmc]
- Familial aggregation of irritable bowel syndrome: a family case-control study. [europepmc]
- Placebos without deception: a randomized controlled trial in irritable bowel syndrome. [europepmc]
- Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. [europepmc]
- IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. [europepmc]
- Therapeutic mechanisms of a mindfulness-based treatment for IBS: effects on visceral sensitivity, catastrophizing, and affective processing of pain sensations. [europepmc]
- Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome. [europepmc]
- Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. [europepmc]
- Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. [europepmc]
- Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome. [europepmc]
- Emotional awareness and expression training improves irritable bowel syndrome: A randomized controlled trial. [europepmc]
- Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial. [europepmc]
- A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. [europepmc]
- Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. [europepmc]
- Treatment with Anaerobutyricum soehngenii: a pilot study of safety and dose-response effects on glucose metabolism in human subjects with metabolic syndrome. [europepmc]
- Efficacy of Zemedy, a Mobile Digital Therapeutic for the Self-management of Irritable Bowel Syndrome: Crossover Randomized Controlled Trial. [europepmc]
- Gut microbial β-glucuronidases regulate host luminal proteases and are depleted in irritable bowel syndrome. [europepmc]
Related